Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Amgen reports topline results from phase III study of talimogene laherparepvec

April 7, 2014

GSK ends MAGRIT study of MAGE-A3 cancer immunotherapeutic

April 2, 2014

RG-7813 enters first clinical trial for cancer

March 31, 2014

Subcutaneous MabThera approved in Europe for two forms of NHL

March 31, 2014

Genmab achieves second milestone in daratumumab collaboration with Janssen

March 28, 2014

Mologen initiates lung cancer trial of MGN-1703 in Belgium

March 27, 2014

Siltuximab receives positive CHMP opinion supporting approval in multicentric Castleman's disease

March 25, 2014

ArevaMed presents phase I data for 212Pb-TCMC-trastuzumab

March 24, 2014

Phase III trial of GSK's MAGE-A3 immunotherapeutic in NSCLC misses first co-primary endpoints

March 21, 2014

Advaxis and UCSF to assess cancer immunotherapy constructs

March 19, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...